Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences ( (PLSE) ) has shared an update.
On May 5, 2026, Pulse Biosciences’ board authorized TD Securities (USA) LLC, acting as sales agent under a February 19, 2026 Equity Distribution Agreement, to sell up to about $60 million of the company’s common stock to one or more company affiliates at prices no lower than the prevailing market price. This expanded flexibility comes as Co-Chairman and 72% shareholder Robert Duggan and CEO and Co-Chairman Paul LaViolette signaled they are likely to buy shares in the near term at market bid prices or better, a move that could reinforce insider confidence and support trading liquidity without diluting value via discounted issuance.
The board’s resolutions allow affiliate participation in the existing at-the-market program while maintaining pricing discipline tied to current market trading levels. Potential purchases by the company’s dominant shareholder and its chief executive, even without binding commitments or specified volumes, may influence market perceptions of the stock and highlight continued insider alignment with other investors.
The most recent analyst rating on (PLSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held down primarily by weak financial performance—minimal revenue, large losses, and elevated cash burn—despite a comparatively supportive low-debt balance sheet. Technicals are constructive with the stock trading above major moving averages, and the earnings call points to strong clinical/regulatory momentum, but valuation remains challenged given ongoing unprofitability and no dividend support.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a medical technology company that issues common stock as part of its corporate financing activities, with significant insider ownership concentrated among its board leadership. The company’s equity structure and capital-raising tools, including an at-the-market offering program, play a central role in its funding strategy and alignment with major shareholders.
Average Trading Volume: 367,048
Technical Sentiment Signal: Buy
Current Market Cap: $1.37B
Learn more about PLSE stock on TipRanks’ Stock Analysis page.